Show your heart a little love this Valentine’s Day.
Take the Listen To Your Heart Challenge!
Everyone who completes the challenge by Heart Valve Disease Awareness Day
(February 22) will be entered to win a $50 Amazon gift card.
The mission of Accelerate Cures/Treatments for All Dementias (ACT-AD) is to support accelerating research and approval for transformational therapies to modify the progression, or relieve symptoms, of all dementias.
ACT-AD brings together companies, advocacy groups, and researchers to interact with the FDA outside of an IND to explore challenges and themes in ADRD clinical development. ACT-AD also provides an overview of research priorities for the NIA and coverage and reimbursement issues for new AD medical products. ACT-AD translates complex regulatory issues to a wide range of stakeholders, including patients and caregivers, to create more engagement on issues that would otherwise be restricted to regulators and companies.
Program objectives are:
Every year the FDA and ACT-AD convene a roundtable meeting to explore the current therapeutic and research landscape for Alzheimer’s disease and related dementias. Sessions address pertinent issues in the field of dementia research and include presentations from NIH/NIA funded investigators and private industry.
The 16th Annual FDA/ACT-AD Allies meeting Dementia Research Inroads: Where are we now? will be held November 16, 2023 at the Renaissance Washington, DC Downtown Hotel, 999 Ninth Street NW, Washington, DC. Attendance is by invitation only. View the agenda.
The 15th Annual FDA/ACT-AD Allies Meeting was held November 16, 2022. Download a PDF summary of the meeting.
The Accelerate Cures/Treatments for All Dementias (ACT-AD) held a webinar on July 13, 2021 for an in-depth…more.
On December 7, 2020, ACT-AD held a webinar on cutting-edge research on Lewy Body dementia (LBD). The webinar…more.
The Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) Coalition held an educational webinar on April 18, 2019 on…more.